Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1984 Mar 17;288(6420):812–813. doi: 10.1136/bmj.288.6420.812

Treatment of hypercalcaemia associated with malignancy.

R Wilkinson
PMCID: PMC1441596  PMID: 6423093

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binstock M. L., Mundy G. R. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med. 1980 Aug;93(2):269–272. doi: 10.7326/0003-4819-93-2-269. [DOI] [PubMed] [Google Scholar]
  2. Brenner D. E., Harvey H. A., Lipton A., Demers L. A study of prostaglandin E2, parathormone, and response to indomethacin in patients with hypercalcemia of malignancy. Cancer. 1982 Feb 1;49(3):556–561. doi: 10.1002/1097-0142(19820201)49:3<556::aid-cncr2820490327>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  3. Chapuy M. C., Meunier P. J., Alexandre C. M., Vignon E. P. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest. 1980 May;65(5):1243–1247. doi: 10.1172/JCI109780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coombes R. S., Ward M. K., Greenberg P. B., Hillyard C. J., Tulloch B. R., Morrison R., Joplin G. F. Calcium metabolism in cancer. Studies using calcium isotopes and immunoassays for parathyroid hormone and calcitonin. Cancer. 1976 Nov;38(5):2111–2120. doi: 10.1002/1097-0142(197611)38:5<2111::aid-cncr2820380539>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  5. Douglas D. L., Duckworth T., Russell R. G., Kanis J. A., Preston C. J., Preston F. E., Prenton M. A., Woodhead J. S. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1980 May 17;1(8177):1043–1047. doi: 10.1016/s0140-6736(80)91496-8. [DOI] [PubMed] [Google Scholar]
  6. Fisken R. A., Heath D. A., Bold A. M. Hypercalcaemia--a hospital survey. Q J Med. 1980 Autumn;49(196):405–418. [PubMed] [Google Scholar]
  7. Hosking D. J., Cowley A., Bucknall C. A. Rehydration in the treatment of severe hypercalcaemia. Q J Med. 1981 Autumn;50(200):473–481. [PubMed] [Google Scholar]
  8. Hosking D. J. Disequilibrium hypercalcaemia. Br Med J (Clin Res Ed) 1983 Jan 29;286(6362):326–327. doi: 10.1136/bmj.286.6362.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jacobs T. P., Siris E. S., Bilezikian J. P., Baquiran D. C., Shane E., Canfield R. E. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med. 1981 Mar;94(3):312–316. doi: 10.7326/0003-4819-94-3-312. [DOI] [PubMed] [Google Scholar]
  10. Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med. 1982 Feb;72(2):221–226. doi: 10.1016/0002-9343(82)90813-0. [DOI] [PubMed] [Google Scholar]
  11. Kiang D. T., Loken M. K., Kennedy B. J. Mechanism of the hypocalcemic effect of mithramycin. J Clin Endocrinol Metab. 1979 Feb;48(2):341–344. doi: 10.1210/jcem-48-2-341. [DOI] [PubMed] [Google Scholar]
  12. Mundy G. R., Raisz L. G. Drugs for disorders of bone: pharmacological and clinical considerations. Drugs. 1974;8(4):250–289. doi: 10.2165/00003495-197408040-00003. [DOI] [PubMed] [Google Scholar]
  13. Mundy G. R., Wilkinson R., Heath D. A. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med. 1983 Mar;74(3):421–432. doi: 10.1016/0002-9343(83)90961-0. [DOI] [PubMed] [Google Scholar]
  14. Perlia C. P., Gubisch N. J., Wolter J., Edelberg D., Dederick M. M., Taylor S. G., 3rd Mithramycin treatment of hypercalcemia. Cancer. 1970 Feb;25(2):389–394. doi: 10.1002/1097-0142(197002)25:2<389::aid-cncr2820250217>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  15. Raisz L. G., Trummel C. L., Wener J. A., Simmons H. Effect of glucocorticoids on bone resorption in tissue culture. Endocrinology. 1972 Apr;90(4):961–967. doi: 10.1210/endo-90-4-961. [DOI] [PubMed] [Google Scholar]
  16. Slayton R. E., Shnider B. I., Elias E., Horton J., Perlia C. P. New approach to the treatment of hypercalcemia. The effect of short-term treatment with mithramycin. Clin Pharmacol Ther. 1971 Sep-Oct;12(5):833–837. doi: 10.1002/cpt1971125833. [DOI] [PubMed] [Google Scholar]
  17. Sleeboom H. P., Bijvoet O. L., van Oosterom A. T., Gleed J. H., O'Riordan J. L. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet. 1983 Jul 30;2(8344):239–243. doi: 10.1016/s0140-6736(83)90231-3. [DOI] [PubMed] [Google Scholar]
  18. Strumpf M., Kowalski M. A., Mundy G. R. Effects of glucocorticoids on osteoclast-activating factor. J Lab Clin Med. 1978 Nov;92(5):772–778. [PubMed] [Google Scholar]
  19. Suki W. N., Yium J. J., Von Minden M., Saller-Hebert C., Eknoyan G., Martinez-Maldonado M. Acute treatment of hypercalcemia with furosemide. N Engl J Med. 1970 Oct 15;283(16):836–840. doi: 10.1056/NEJM197010152831603. [DOI] [PubMed] [Google Scholar]
  20. Thalassinos N. C., Joplin G. F. Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet. 1970 Sep 12;2(7672):537–538. doi: 10.1016/s0140-6736(70)91345-0. [DOI] [PubMed] [Google Scholar]
  21. van Breukelen F. J., Bijvoet O. L., van Oosterom A. T. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):803–805. doi: 10.1016/s0140-6736(79)91319-9. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES